MET and metastasis: Especially FGFR1 (13% in PTvs.N and 7% in Mvs.PT to 10% in AMP), FGFR3 (7% in PTvs.N and Mvs.PT to 2% in AMP), DDR2 in lymph node metastasis (13% in Mvs.PT to 3% in AMP) and MET (7% in PTvs.N and Mvs.PT to 2% AMP, FC 2.4; Fig. S28) seem to be similarly overexpressed.